Adjuvant Chemotherapy Advances Boost Outcomes in GI Malignancies

Jason Harris
Published: Monday, Jun 18, 2018
Diane Reidy-Lagunes, MD

Diane Reidy-Lagunes, MD
Improved chemotherapy combination regimens are enhancing outcomes for patients across a range of gastrointestinal (GI) cancers, according to Diane Reidy-Lagunes, MD, who reviewed practice-changing findings during a presentation at the 3rd Annual School of Gastrointestinal Oncology™ (SOGO®).

hosted April 28 in New York City. She detailed findings from pivotal studies in gastric, pancreatic, biliary, and colorectal cancers to give her audience an overview of the field.

Evolving Options in Gastric Cancer

In gastric cancer, results from the FLOT4 clinical trial suggest that the FLOT (fluorouracil/leucovorin, oxaliplatin, and docetaxel [Taxotere]) regimen should be the adjuvant treatment of choice in gastric cancer over epirubicin/cisplatin/fluorouracil (ECF) or epirubicin/cisplatin/oxaliplatin (ECX).1

There was no difference in operative morbidity/mortality between the treatment groups, Reidy-Lagunes added. Furthermore, there were no differences in terms of complications, death at 30 or 90 days, or number of hospitalization days.

New Standard in Pancreatic Setting

The 5-year survival rate for stage Ia pancreatic cancer is 14%, dropping to 3% for stage III disease and about 1% for stage IV, according to the American Cancer Society. The disease accounts for 3% of all cancers but 7% of cancer deaths.2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication